

May 4, 2015



## Corbus Pharmaceuticals to Present at the Cystic Fibrosis Workshop Hosted by JMP Securities on May 8, 2015

NORWOOD, MA -- (Marketwired) -- 05/04/15 -- [Corbus Pharmaceuticals Holdings, Inc.](#) (NASDAQ: CRBP) (the Company), a clinical stage drug development company targeting rare, life-threatening inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the Cystic Fibrosis (CF) Workshop hosted by JMP Securities on Friday, May 8, 2015, at 10:35 a.m. EDT at The Langham hotel in Boston, MA.

Corbus is preparing to commence a Phase 2, first-in-patient, clinical study with [Resunab](#)<sup>™</sup>, its novel synthetic oral drug that has the potential to treat the chronic pulmonary inflammation and fibrosis associated with the disease progression of CF, regardless of an individual's specific CFTR gene mutation.

Dr. Cohen will discuss key milestones achieved by the Company, including the [recently announced \\$5 million Development Award](#) from the [Cystic Fibrosis Foundation Therapeutics, Inc.](#) (CFFT) to help support Corbus' upcoming Phase 2 international clinical trial of Resunab in adults with CF.

Corbus has submitted its Phase 2 clinical protocol for the treatment of CF with Resunab to the U.S. Food and Drug Administration (FDA) and anticipates beginning the study in the U.S. as early as this quarter (2Q 2015), pending FDA clearance of the protocol. The European filing will follow shortly thereafter.

### ***About Cystic Fibrosis***

CF is a life-threatening, genetic disease that primarily affects the lungs and digestive system. It effects about 30,000 people in the United States (70,000 worldwide). People with CF inherit a defective CFTR gene that results in reduced chloride transport, heightened immune responses and a build-up of thick mucus in the lungs, pancreas and other organs. The thick mucus traps bacteria in the airways resulting in infections and more inflammation. The chronic unresolved lung inflammation leads to severe lung damage and respiratory failure. Respiratory problems are the most serious and persistent complication for individuals with CF. For more information on cystic fibrosis, go to [www.cff.org](http://www.cff.org).

### ***About Resunab***<sup>™</sup>

Resunab<sup>™</sup> is a novel synthetic oral drug with unique activity that has been shown to resolve inflammation and pro-fibrotic processes. Pre-clinical models and Phase 1 clinical studies

have shown Resunab to have a favorable safety profile coupled with promising potency in pre-clinical models of inflammation and fibrosis. Resunab binds to the CB2 receptor on immune cells and triggers resolution of inflammation and reduction of pro-inflammatory pathways, in effect turning chronic inflammation "off" without causing immunosuppression.

### ***About Corbus Pharmaceuticals***

Corbus Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. Our lead product candidate Resunab™ is a novel oral drug that resolves chronic inflammation and pro-fibrotic processes. Resunab is scheduled to commence Phase 2 clinical trials for the treatment of cystic fibrosis and diffuse cutaneous systemic sclerosis (scleroderma) in 2015. For more information, please visit [www.CorbusPharma.com](http://www.CorbusPharma.com).

### ***Forward-Looking Statements***

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

### ***Investor Contact***

Jenene Thomas  
Investor Relations and Corporate Communications Advisor  
Jenene Thomas Communications, LLC  
Phone: +1 (908) 938-1475  
Email: [Email Contact](mailto:jenene@corbuspharma.com)

### ***Media Contact***

David Schull or Marissa Goberdhan  
Russo Partners, LLC  
Phone: +1 (858) 717-2310

Email: [Email Contact](#)

Email: [Email Contact](#)

Source: Corbus Pharmaceuticals Holdings, Inc.